IL302972A - Medicine for alleviating neuropathic pain - Google Patents

Medicine for alleviating neuropathic pain

Info

Publication number
IL302972A
IL302972A IL302972A IL30297223A IL302972A IL 302972 A IL302972 A IL 302972A IL 302972 A IL302972 A IL 302972A IL 30297223 A IL30297223 A IL 30297223A IL 302972 A IL302972 A IL 302972A
Authority
IL
Israel
Prior art keywords
receptor
pain
compound
patient
neuropathic pain
Prior art date
Application number
IL302972A
Other languages
English (en)
Hebrew (he)
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of IL302972A publication Critical patent/IL302972A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL302972A 2020-11-30 2021-11-26 Medicine for alleviating neuropathic pain IL302972A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020199206 2020-11-30
PCT/JP2021/043375 WO2022114122A1 (ja) 2020-11-30 2021-11-26 神経障害性疼痛を緩和させるための医薬

Publications (1)

Publication Number Publication Date
IL302972A true IL302972A (en) 2023-07-01

Family

ID=81755628

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302972A IL302972A (en) 2020-11-30 2021-11-26 Medicine for alleviating neuropathic pain

Country Status (11)

Country Link
US (1) US20240009180A1 (https=)
EP (1) EP4272758A4 (https=)
JP (1) JPWO2022114122A1 (https=)
KR (1) KR20230096055A (https=)
CN (1) CN116782901A (https=)
AU (1) AU2021389409A1 (https=)
CA (1) CA3198258A1 (https=)
IL (1) IL302972A (https=)
MX (1) MX2023006289A (https=)
TW (1) TW202237111A (https=)
WO (1) WO2022114122A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121159455A (zh) * 2024-06-18 2025-12-19 武汉人福创新药物研发中心有限公司 氨基酯类化合物及其作为p2x7拮抗剂的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013269606B2 (en) 2012-06-01 2018-05-17 Ablynx N.V. P2X7 receptor antagonists and agonists
JP6301920B2 (ja) 2013-05-27 2018-03-28 国立大学法人 岡山大学 疼痛治療薬
US11077100B2 (en) * 2017-03-13 2021-08-03 Raqualia Pharma Inc. Tetrahydroquinoline derivatives as P2X7 receptor antagonists
EP3398941A1 (en) 2017-05-03 2018-11-07 AXXAM S.p.A. Heterocyclic p2x7 antagonists
JP7311944B2 (ja) 2018-04-16 2023-07-20 塩野義製薬株式会社 二環性含窒素複素環誘導体を含有する医薬組成物
JP2019182806A (ja) 2018-04-16 2019-10-24 塩野義製薬株式会社 二環性複素環誘導体およびそれらを含有する医薬組成物

Also Published As

Publication number Publication date
CN116782901A (zh) 2023-09-19
WO2022114122A1 (ja) 2022-06-02
US20240009180A1 (en) 2024-01-11
KR20230096055A (ko) 2023-06-29
EP4272758A1 (en) 2023-11-08
EP4272758A4 (en) 2025-01-29
JPWO2022114122A1 (https=) 2022-06-02
CA3198258A1 (en) 2022-06-02
MX2023006289A (es) 2023-07-31
TW202237111A (zh) 2022-10-01
AU2021389409A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
Alsaloum et al. Status of peripheral sodium channel blockers for non-addictive pain treatment
Maarup et al. Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann–Pick C1
IL257276A (en) Methods for treating Knox-Gestaut syndrome using penforamine
JP6250394B2 (ja) 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
IL257744A (en) Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
IL255148B (en) 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
Farlow Treatment of mild cognitive impairment (MCI)
CN101631547A (zh) 使用地莫本和多奈哌齐治疗阿尔茨海默病的组合疗法
JP2020520947A (ja) 熱ショックタンパク質誘導因子および前頭側頭障害
IL302972A (en) Medicine for alleviating neuropathic pain
CN114504579B (zh) 一种预防、治疗疼痛、炎症的化合物及其应用
JP2024543347A (ja) 筋萎縮性側索硬化症を治療する方法およびそれに対する投与計画
US20250381197A1 (en) Regimen for Treating Amyotrophic Lateral Sclerosis Having Onset 24 Months Prior to Treatment
HK40094114A (en) Medicine for alleviating neuropathic pain
US20260000662A1 (en) Use of arimoclomol in activating clear gene expression as treatment for lysosomal storage disorders
US20260000661A1 (en) Use of arimoclomol in activating clear gene expression as treatment for lysosomal storage disorders
Smith Muscarinic Acetylcholine Receptor 1: Implications for Precision Medicine and Rett Syndrome Therapeutics
KR20100080550A (ko) Ｔｒｐｖ1 매개성 질환 치료제
WO2026010893A1 (en) Arimoclomol in combination with miglustat for use in the treatment of lysosomal storage disorders such as niemann-pick disease, type-c
WO2026010894A1 (en) Arimoclomol in combination with miglustat for use in the treatment of lysosomal storage disorders
AU2018376605B2 (en) A novel method of treating dystonia
JP2024537981A (ja) 筋萎縮性側索硬化症を治療する方法
Siever et al. Cognitive enhancement trial with guanfacine in SPD
Barkhuizen Genetic and perinatal risk factors for movement disorders
Bianco et al. We report 2 cases of adult-onset ECD with neu-rologic involvement and strikingly similar brain MRI pattern of abnormalities.